search

Active clinical trials for "Carcinoma, Renal Cell"

Results 111-120 of 1644

A Phase 1/2 Study of BA3071

Solid TumorAdult8 more

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Recruiting13 enrollment criteria

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Solid TumorClear Cell Renal Cell Carcinoma7 more

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Recruiting35 enrollment criteria

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Metastatic TumorRenal Cell Carcinoma1 more

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

Recruiting38 enrollment criteria

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line...

CarcinomaRenal Cell

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Recruiting27 enrollment criteria

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients...

Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck Carcinoma61 more

This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may shrink or stabilize cancer in patients undergoing treatment for HIV.

Recruiting80 enrollment criteria

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

Papillary Renal Cell Carcinoma Type 2

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)

Recruiting45 enrollment criteria

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma...

ccRCCClear Cell Renal Cell Carcinoma8 more

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 Dose (RP2D) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Recruiting13 enrollment criteria

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma...

MelanomaRenal Cell Carcinoma5 more

This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).

Recruiting55 enrollment criteria

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Immunotherapy

This is an experimental study to evaluate the safety and efficacy of CAR T cells targeting CAIX in the treatment of advanced renal cancer.

Recruiting17 enrollment criteria

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal...

Non-Clear Cell Renal Cell Carcinoma

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

Recruiting21 enrollment criteria
1...111213...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs